Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Single Centre, Phase I Study to Evaluate the Safety, Reactogenicity and Immunogenicity of AstriVax' Investigational Therapeutic Hepatitis B Virus (HBV) Vaccine (AVX70371) in Healthy Adults Aged 18 to 40 Years

NCT06989788 is registered in ClinicalTrials.gov with AstriVax Therapeutics as lead sponsor.

NCT NCT06989788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06989788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Single Centre, Phase I Study to Evaluate the Safety, Reactogenicity and Immunogenicity of AstriVax' Investigational Therapeutic Hepatitis B Virus (HBV) Vaccine (AVX70371) in Healthy Adults Aged 18 to 40 Years
Lead sponsor
AstriVax Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
May 6, 2025
Completion date
August 10, 2026
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b